Shares of ImmuPharma plc (LON:IMM – Get Free Report) rose 22.9% on Friday . The stock traded as high as GBX 4.70 ($0.06) and last traded at GBX 4.30 ($0.05). Approximately 64,504,590 shares were traded during mid-day trading, an increase of 155% from the average daily volume of 25,253,549 shares. The stock had previously closed at GBX 3.50 ($0.04).
ImmuPharma Price Performance
The firm has a 50-day simple moving average of GBX 1.40 and a 200 day simple moving average of GBX 1.65. The firm has a market cap of £16.66 million, a PE ratio of -400.00 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
Featured Stories
- Five stocks we like better than ImmuPharma
- Technology Stocks Explained: Here’s What to Know About Tech
- EV Sales Are Hitting Record Highs: 3 ETFs That Can Benefit
- ETF Screener: Uses and Step-by-Step Guide
- 3 Reasons Palo Alto May Be the Best Cybersecurity Stock in 2025
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- ServiceNow Targets New Highs With AI and Automation
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
